Sarcoma UK Flag of Scotland
Monday, April 13, 2015

The Scottish Medicines Consortium (SMC) has approved regorafenib for the treatment of adult patients with unresectable or metastatic GIST whose condition has progressed on or who have been unable to tolerate imatinib and sunitinib. The decision came out of the SMC’s new PACE process that takes into account the views of patients and clinicians, and the rarity of the condition.

For more information: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1031_15_regorafenib_Stivarga/Briefing_note_regorafenib_Stivarga